Florent Soubrier

Active 1983–2024

97
Papers
25,350
Citations
78
h-index
97
i10-index

Citations

Citations per year for Florent Soubrier1982: 1 citations1984: 6 citations1985: 1 citations1986: 4 citations1987: 6 citations1988: 4 citations1989: 5 citations1990: 7 citations1991: 16 citations1992: 31 citations1993: 68 citations1994: 127 citations1995: 196 citations1996: 182 citations1997: 215 citations1998: 225 citations1999: 157 citations2000: 261 citations2001: 167 citations2002: 145 citations2003: 154 citations2004: 131 citations2005: 125 citations2006: 120 citations2007: 87 citations2008: 109 citations2009: 110 citations2010: 128 citations2011: 85 citations2012: 93 citations2013: 141 citations2014: 108 citations2015: 112 citations2016: 120 citations2017: 94 citations2018: 152 citations2019: 348 citations2020: 518 citations2021: 411 citations2022: 409 citations2023: 233 citations2024: 383 citations2025: 153 citations2026: 1 citations1983: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,554 citing papers, 25.7% of this breakdownUnited Kingdom: 608 citing papers, 10.1% of this breakdownFrance: 557 citing papers, 9.2% of this breakdownGermany: 379 citing papers, 6.3% of this breakdownChina: 306 citing papers, 5.1% of this breakdownJapan: 243 citing papers, 4% of this breakdownCanada: 237 citing papers, 3.9% of this breakdownNetherlands: 221 citing papers, 3.7% of this breakdownItaly: 204 citing papers, 3.4% of this breakdownAustralia: 184 citing papers, 3% of this breakdownSpain: 146 citing papers, 2.4% of this breakdownBelgium: 97 citing papers, 1.6% of this breakdown
0%25.7%Other 21.6%

Fields

  • Medicine71.6%
  • Biochemistry, Genetics and Molecular Biology23.2%
  • Neuroscience1.7%
  • Immunology and Microbiology0.9%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Nursing0.4%
  • Other1.7%

Topics

  • Renin-Angiotensin System Studies8.3%
  • Pulmonary Hypertension Research and Treatments8.1%
  • Hormonal Regulation and Hypertension5%
  • Nitric Oxide and Endothelin Effects2.1%
  • Apelin-related biomedical research1.9%
  • Genetic Associations and Epidemiology1.9%
  • Other72.7%

Coauthors

All papers

Open in search
  1. Genetics and genomics of pulmonary arterial hypertension

    Authors: , , , , , , , - European Respiratory Journal 2018 cited by 468

  2. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2016 cited by 451

  3. Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning

    Authors: , , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2020 cited by 101

  4. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Girerd, Arjan C. Houweling, Luke Howard, Marc Humbert, David G. Kiely, Gábor Kovács, Robert V. MacKenzie Ross, Shahin Moledina, David Montani, Michael Newnham, Andrea Olschewski, Horst Olschewski, Andrew J. Peacock, Joanna Pepke‐Żaba, Inga Prokopenko, Christopher J. Rhodes, Laura Scelsi, Werner Seeger, Florent Soubrier, Dan F. Stein, Jay Suntharalingam, Emilia M. Swietlik, Mark Toshner, David A. van Heel, Anton Vonk Noordegraaf, Quinten Waisfisz, John Wharton, Stephen J. Wort, Willem H. Ouwehand, Nicole Soranzo, Allan Lawrie, Paul D. Upton, Martin R. Wilkins, Richard C. Trembath, Nicholas W. Morrell - Nature Communications 2018 cited by 384

  5. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

    Authors: , , , , , - Journal of Clinical Investigation 1990 cited by 3,805

  6. Pulmonary veno-occlusive disease

    Authors: , , , , , , , , , , , , , , - European Respiratory Journal 2016 cited by 512

  7. Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tae‐Hwi Schwantes‐An, Stephen J. Wort, Martin R. Wilkins, Seán Gaine, Nicholas W. Morrell, Paul A. Corris - European Respiratory Journal 2021 cited by 90

  8. Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Girerd, Arjan C. Houweling, Luke Howard, Marc Humbert, David G. Kiely, Gábor Kovács, Allan Lawrie, Robert V. MacKenzie Ross, Shahin Moledina, David Montani, Andrea Olschewski, Horst Olschewski, Willem H. Ouwehand, Andrew J. Peacock, Joanna Pepke‐Żaba, Inga Prokopenko, Christopher J. Rhodes, Laura Scelsi, Werner Seeger, Florent Soubrier, Jay Suntharalingam, Mark Toshner, Richard C. Trembath, Anton Vonk Noordegraaf, Stephen J. Wort, Martin R. Wilkins, Paul B. Yu, Wei Li, Stefan Gräf, Paul D. Upton, Nicholas W. Morrell - American Journal of Respiratory and Critical Care Medicine 2019 cited by 125

  9. Screening for pulmonary arterial hypertension in adults carrying aBMPR2mutation

    Authors: , , , , , , , , , , , , , , , , , , , - European Respiratory Journal 2020 cited by 105

  10. Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 ( ALK1 ) Mutation

    Authors: , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2010 cited by 296

  11. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension

    Authors: , , , , , , , , , , , , , , , - Nature Genetics 2013 cited by 453

  12. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2017 cited by 178

  13. A Novel Channelopathy in Pulmonary Arterial Hypertension

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 470

  14. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paula Rayner-Matthews, Olga Shamardina, Florent Soubrier, Laura Southgate, Jay Suntharalingam, Mark Toshner, Richard C. Trembath, Anton Vonk Noordegraaf, Martin R. Wilkins, Stephen J. Wort, John Wharton, Stefan Gräf, Nicholas W. Morrell, Timothy J. Aitman, David Bennett, Mark J. Caulfield, Patrick F. Chinnery, Daniel P. Gale, Ania Koziell, Taco W. Kuijpers, Michael Laffan, Eamonn R. Maher, Hugh S. Markus, Willem H. Ouwehand, David J. Perry, F. Lucy Raymond, Irene Roberts, Kenneth G. C. Smith, Adrian J. Thrasher, Hugh Watkins, Catherine Williamson, Geoffrey Woods, Sofie Ashford, John R. Bradley, Debra Fletcher, Tracey Hammerton, Roger James, Nathalie Kingston, Willem H. Ouwehand, Christopher J. Penkett, F. Lucy Raymond, Kathleen Stirrups, Marijke Veltman, Tim Young, Sofie Ashford, Matthew A. Brown, Emma Clement, John Davis, Eleanor Dewhurst, Marie Erwood, Amy Frary, Rachel Linger, Sofia Papadia, Karola Rehnström, Hannah Stark, David Allsup, Steve Austin, Tamam Bakchoul, Tadbir K. Bariana, Paula Bolton‐Maggs, Elizabeth Chalmers, Peter Collins, Wendy N. Erber, Tamara Everington, Rémi Favier, Kathleen Freson, Bruce Furie, Michael Gattens, Keith Gomez, Daniel Greene and 225 more - Circulation 2017 cited by 145

  15. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH

    Authors: , , , , , , , , , , - European Respiratory Journal 2022 cited by 57

  16. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects

    Authors: , , , , , , , , , , , , , , , , , , , , , - Human Mutation 2015 cited by 228

  17. Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases

    Authors: , , , , , , , , , , , , , , , , , , - European Respiratory Journal 2018 cited by 107

  18. Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Harrison W. Farber, Robert P. Frantz, Jean Elwing, Nicholas S. Hill, D. Dunbar Ivy, James Klinger, Steven D. Nathan, Ronald J. Oudiz, Ivan M. Robbins, Robert Schilz, Terry Fortin, Jeffrey Wilt, Delphine Yung, Eric D. Austin, Ferhaan Ahmad, Nitin Bhatt, Tim Lahm, Adaani Frost, Zeenat Safdar, Zia Ur Rehman, Robert Walter, Fernando Torres, Sahil Bakshi, Stephen L. Archer, Rahul Argula, Christopher F. Barnett, Raymond L. Benza, Ankit A. Desai, Veeranna Maddipati, Harm Jan Bogaard, Colin Church, Gerry Coghlin, Robin Condliffe, Mélanie Eyries, Henning Gall, Stefano Ghio, Barbara Girerd, Simon Holden, Luke Howard, Marc Humbert, David G. Kiely, Gábor Kovács, Jim Lordan, Rajiv D. Machado, Robert V. MacKenzie Ross, Colm McCabe, Jennifer M. Martin, Shahin Moledina, David Montani, Horst Olschewski, Christopher J. Penkett, Joanna Pepke‐Żaba, Laura Price, Christopher J. Rhodes, Werner Seeger, Florent Soubrier, Laura Southgate, Jay Suntharalingam, Andrew J. Swift, Mark Toshner, Carmen Treacy, Anton Vonk Noordegraaf, John Wharton, Jim M. Wild, Stephen J. Wort, National Cohort Study of Idiopathic and Heritable PAH, Harm Jan Bogaard, Colin Church, Gerry Coghlin, Robin Condliffe and 37 more - Genome Medicine 2021 cited by 85

  19. Molecular basis of human hypertension: Role of angiotensinogen

    Authors: , , , , , , , , , , - Cell 1992 cited by 1,862

  20. Genetics and Genomics of Pulmonary Arterial Hypertension

    Authors: , , , , , , , , , , - Journal of the American College of Cardiology 2013 cited by 620

  21. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thierry Frébourg, Jean–François Fléjou, Natacha Entz‐Werlé, Julie Leclerc, David Malka, Odile Cohen‐Haguenauer, Yael Goldberg, Anne‐Marie Gerdes, Faten Fedhila, Michèle Mathieu‐Dramard, Richard Hamelin, Wafaa Badre, Marion Gauthier‐Villars, Franck Bourdeaut, Eamonn Sheridan, Hans F. A. Vasen, Laurence Brugières, Katharina Wimmer, Martine Muleris, Alex Duval - Gastroenterology 2015 cited by 97

  22. BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension

    Authors: , , , , , , , , , , , , , , - European Respiratory Journal 2016 cited by 92

  23. Phenotype and outcome of pulmonary arterial hypertension patients carrying aTBX4mutation

    Authors: , , , , , , , , , , , , , , , , , , , , , , - European Respiratory Journal 2020 cited by 73

  24. Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension

    Authors: , , , , , , , , , , , , , , , , , , - European Respiratory Journal 2019 cited by 42